Last updated: 2026-04-03
A significant regulatory shift is on the horizon for manufacturers of tuberculosis (TB) diagnostic devices. On March 30, 2026, the U.S. Food and Drug Administration published a proposed rule in the Federal Register — Docket No. FDA-2026-06064 — proposing to reclassify two categories of Mycobacterium tuberculosis (MTB) cell-mediated immunity tests from Class III (Premarket Approval) to Class II (Special Controls), subject to premarket notification (510(k)). This is a meaningful reduction in regulatory burden that, if finalized, will reshape the market entry pathway for these devices — and manufacturers need to start preparing now.
This article breaks down exactly what is changing, what stays the same, who is affected, and what practical steps your organization should take to remain compliant throughout this transition.
What Is Being Reclassified — and Why It Matters
The proposed reclassification applies to two specific device product codes under the microbiology device umbrella:
- Product Code NCD — Mycobacterium tuberculosis cell-mediated immunity tests, intended as an aid in the diagnosis of MTB infection
- Product Code OJN — Mycobacterium tuberculosis cell-mediated immune response enzyme-linked immunospot (ELISpot) tests, also intended as an aid in the diagnosis of MTB infection
Both product codes are currently classified as postamendments Class III devices, meaning they require Premarket Approval (PMA) — the most rigorous and resource-intensive FDA marketing authorization pathway. A PMA application requires extensive clinical data demonstrating reasonable assurance of safety and effectiveness, and the process can take years and cost millions of dollars.
Under the proposed rule, these devices would move to Class II (Special Controls), requiring only a 510(k) premarket notification — a substantially less burdensome pathway that relies on demonstrating substantial equivalence to a legally marketed predicate device. FDA also proposes to establish Special Controls that would define the performance requirements devices in this class must meet to provide reasonable assurance of safety and effectiveness.
Citation hook: FDA's proposed reclassification of MTB cell-mediated immunity tests from Class III to Class II represents the agency's determination that general controls and special controls are sufficient to provide reasonable assurance of safety and effectiveness for these devices, eliminating the PMA requirement for this category.
Globally, tuberculosis remains a critical public health challenge. According to the World Health Organization's 2024 Global Tuberculosis Report, TB caused an estimated 1.25 million deaths in 2023, making it one of the leading infectious disease killers worldwide. In the United States, the CDC reported 8,331 TB cases in 2023 — underscoring the continued clinical need for accurate, accessible diagnostic tools.
The reclassification is significant precisely because it lowers the barrier to market for manufacturers of these critical diagnostic tests, which could ultimately improve diagnostic access for patients and healthcare providers.
Understanding the Regulatory Framework: Class III vs. Class II
If you're not deeply familiar with FDA's device classification system, it's worth a quick orientation before diving into the compliance implications.
| Feature | Class III (Current) | Class II (Proposed) |
|---|---|---|
| Regulatory Pathway | Premarket Approval (PMA) | 510(k) Premarket Notification |
| Standard of Evidence | Valid scientific evidence of safety & effectiveness | Substantial equivalence to predicate |
| Typical Timeline | 180+ days (often 2–5 years with iterations) | 90–180 days average |
| Average Cost | $1M–$5M+ | $50K–$500K |
| Post-Market Requirements | PMA supplements for changes, Annual Reports | Special Controls compliance, 510(k) for significant changes |
| Clinical Data Required | Yes — extensive clinical studies typically required | Often reduced; performance data per Special Controls |
| Market Competitors | Fewer (higher barrier) | More accessible to new entrants |
This table illustrates why reclassification matters: moving from PMA to 510(k) dramatically reduces both the time and financial investment required to bring a new MTB diagnostic device to the U.S. market. That said, manufacturers should not interpret "less burdensome" as "no burden." Class II Special Controls can be rigorous, and 510(k) submissions still require thorough documentation and performance testing.
What Are Special Controls — and What Will They Require?
When FDA reclassifies a device to Class II, it typically establishes Special Controls — a set of device-specific requirements that address risks that general controls alone cannot adequately mitigate. For MTB cell-mediated immunity tests, the Special Controls proposed by FDA are expected to address:
- Clinical performance requirements — sensitivity, specificity, and positive/negative predictive values benchmarks for MTB detection
- Labeling requirements — including appropriate indications for use, limitations, and intended patient population disclosures
- Device description requirements — detailed characterization of device components, assay design, and principle of operation
- Performance testing protocols — including interference studies, reproducibility data, and stability testing
- Post-market surveillance obligations — mechanisms to detect and report performance issues in real-world use
The exact Special Controls language will be published in the final rule. Manufacturers should review the proposed rule text carefully at the Federal Register docket (FDA-2026-06064) and begin mapping their existing quality systems and technical documentation against the expected requirements.
Citation hook: Under FDA's proposed framework, Special Controls for MTB cell-mediated immunity tests are designed to be device-specific mitigation measures that, in combination with general controls, provide reasonable assurance of safety and effectiveness without requiring the full Premarket Approval process.
Who Is Affected by This Proposed Rule?
This reclassification has broad implications across several stakeholder groups:
Current PMA Holders (Product Codes NCD and OJN)
If you currently hold a PMA for a device in either of these product codes, you will want to monitor the final rule closely. Once the reclassification is effective, FDA has historically provided a transition pathway for existing PMA holders — often allowing them to continue marketing under their existing PMA while transitioning to a 510(k)-based framework. However, future design changes or manufacturing changes that would normally require a PMA supplement may instead proceed through a 510(k) or Special Controls compliance pathway. This could significantly simplify your change management and post-market obligations.
New Market Entrants
For companies that have been deterred from entering the MTB diagnostics space due to the PMA barrier, this reclassification opens the door. If finalized, companies could pursue a 510(k) submission — a far more attainable regulatory milestone — to bring competing diagnostic products to market. This is the kind of regulatory action that reshapes competitive landscapes.
In Vitro Diagnostic (IVD) Manufacturers with Adjacent Products
If your portfolio includes other infectious disease diagnostics or immunological assays, this reclassification signals FDA's broader appetite for reducing regulatory burden on established, well-understood diagnostic technologies. Watch this space — similar reclassifications may follow for other product codes.
Clinical Laboratories and Healthcare Providers
While laboratories don't submit regulatory filings, they are downstream beneficiaries of reclassification. More manufacturers entering the market via a streamlined pathway means greater product competition, potential cost reductions, and — critically — more diagnostic options for clinicians managing TB patients and high-risk populations.
Key Effective Dates and Compliance Deadlines
This is a proposed rule, meaning it is not yet final. Here is the regulatory timeline manufacturers should track:
| Milestone | Date / Timeframe |
|---|---|
| Proposed Rule Published | March 30, 2026 |
| Public Comment Period Opens | March 30, 2026 |
| Public Comment Period Closes | Typically 60–90 days after publication (confirm at Regulations.gov) |
| Final Rule Publication | TBD — typically 6–18 months post-comment period |
| Final Rule Effective Date | TBD — typically 30–90 days after final rule publication |
| Transition Period for Existing PMA Holders | TBD — to be specified in the final rule |
Action item: Submit comments to the FDA docket during the public comment period if you have data, clinical experience, or operational insights that should inform the final rule. Manufacturers and laboratory stakeholders who engage during the comment period often have meaningful influence on the final Special Controls language.
I strongly encourage any manufacturer currently holding or pursuing a PMA for Product Codes NCD or OJN to contact a qualified regulatory affairs consultant before the comment period closes. The Special Controls that FDA finalizes will govern your device's compliance posture for years to come — your input now can shape more workable requirements.
Practical Compliance Guidance: What to Do Right Now
Whether you are an existing PMA holder or a new market entrant planning a future 510(k), here are the concrete steps you should take in response to this proposed rule.
Step 1: Read the Full Proposed Rule
The complete text is available at the Federal Register: FDA-2026-06064. Pay particular attention to FDA's articulation of the proposed Special Controls and the agency's rationale for reclassification. FDA's reasoning often telegraphs what the final rule will prioritize.
Step 2: Conduct a Gap Analysis Against Proposed Special Controls
Even before the final rule is published, begin a preliminary gap analysis comparing your current technical file, Design History File (DHF), and Device Master Record (DMR) against the proposed Special Controls requirements. Identify areas where your existing performance data may not satisfy the new requirements, and flag where new testing or documentation may be needed.
Step 3: Assess Your Current PMA Obligations
If you hold a PMA, work with your regulatory team to map out what changes you anticipate making to your device over the next 1–3 years. Determine which of those changes would require a PMA supplement under the current framework and assess how the reclassification might alter that calculus. This exercise informs your post-market strategy and resource planning.
Step 4: Engage During the Public Comment Period
As noted, the comment period is your opportunity to influence the final Special Controls. If you have clinical data, analytical performance data, or operational experience with MTB diagnostics that is relevant to FDA's proposed requirements, consider submitting a formal comment. Comments should be specific, data-driven, and focused on ensuring the Special Controls are both protective and workable.
Step 5: Update Your Regulatory Strategy and Budget
A transition from PMA to 510(k) changes your regulatory budget, timeline, and resource allocation. Update your regulatory affairs roadmap to account for the new pathway. If you have been deferring an MTB product launch due to PMA requirements, now is the time to revisit that decision with a fresh regulatory strategy.
Step 6: Monitor the Docket for Final Rule Publication
Set up alerts on the FDA website and Regulations.gov for updates to Docket No. FDA-2026-06064. The final rule will include the definitive Special Controls language, the effective date, and any transition provisions for existing PMA holders.
Why This Reclassification Reflects a Broader FDA Trend
This proposed reclassification is consistent with FDA's longstanding policy under the Medical Device Amendments of 1976 and subsequent legislation to periodically re-evaluate device classifications as technology matures and post-market performance data accumulates. When FDA determines that a device type has a well-characterized safety and effectiveness profile — supported by years of real-world clinical use — the agency will typically propose reclassification to a lower class.
MTB cell-mediated immunity tests, including interferon-gamma release assays (IGRAs) and ELISpot-based tests, have been in clinical use for well over a decade. Devices like QuantiFERON-TB Gold and T-SPOT.TB have generated substantial real-world performance data. The accumulated clinical evidence base appears to have satisfied FDA that Class III controls are no longer necessary to ensure patient safety — a conclusion that reflects the maturation of this diagnostic category.
Citation hook: FDA's periodic reclassification of mature diagnostic technologies from Class III to Class II reflects the agency's evidence-based approach to regulatory burden calibration, ensuring that premarket requirements remain proportionate to residual risk rather than historical uncertainty.
At Certify Consulting, I've worked with over 200 clients navigating FDA's device classification and reclassification processes, and I can say with confidence: the manufacturers who engage early — before the final rule is published — consistently achieve better compliance outcomes than those who wait for effective dates before acting. Our 100% first-time audit pass rate across 8+ years of practice is built on exactly this kind of proactive regulatory positioning.
How Certify Consulting Can Help
Navigating a device reclassification — especially one that changes your premarket pathway from PMA to 510(k) — requires specialized regulatory expertise. At Certify Consulting, we provide:
- Regulatory strategy development tailored to the new 510(k) pathway for Product Codes NCD and OJN
- Gap analysis and technical documentation review against proposed and final Special Controls
- PMA-to-510(k) transition planning for existing PMA holders
- Public comment drafting support to ensure your technical and clinical perspective is heard by FDA
- 510(k) submission preparation including performance testing protocols, substantial equivalence arguments, and labeling review
If your organization manufactures or is planning to develop MTB cell-mediated immunity tests, I'd encourage you to reach out to our team before the public comment window closes. Early engagement is always more cost-effective than reactive compliance remediation.
For more on how FDA classifies and reclassifies medical devices, see our related guidance on navigating FDA's device classification system and our resource on 510(k) premarket notification requirements.
Frequently Asked Questions
What is the difference between the NCD and OJN product codes being reclassified?
Product Code NCD covers Mycobacterium tuberculosis cell-mediated immunity tests broadly (such as interferon-gamma release assays, or IGRAs), while Product Code OJN specifically covers ELISpot-based MTB cell-mediated immune response tests. Both are intended as an aid in the diagnosis of MTB infection and both are subject to this proposed reclassification from Class III to Class II.
Does this reclassification mean existing PMA holders no longer need FDA authorization?
No. Existing PMA holders will continue to require FDA marketing authorization. The reclassification changes the type of authorization required going forward — from PMA to 510(k) — but does not eliminate the need for premarket review. The final rule will specify transition provisions, including whether existing PMA holders must submit a new 510(k) or can continue under their current authorization during a transition period.
When will the reclassification take effect?
The proposed rule was published March 30, 2026. The final rule will be published after the public comment period closes and FDA reviews all submissions. Final rules for device reclassifications typically take effect 30–90 days after publication. Manufacturers should monitor Docket No. FDA-2026-06064 on Regulations.gov for updates.
What are Special Controls and how do they affect my 510(k) submission?
Special Controls are device-specific requirements established by FDA for Class II devices that, together with general controls, provide reasonable assurance of safety and effectiveness. For MTB immunity tests, these are expected to include clinical performance benchmarks, labeling requirements, and performance testing protocols. Your 510(k) submission must demonstrate compliance with the applicable Special Controls to receive clearance.
Should I submit a public comment on this proposed rule?
If your organization manufactures, develops, or has clinical experience with MTB cell-mediated immunity tests, submitting a comment during the public comment period is strongly advisable. Comments that are data-driven and specific can directly influence the final Special Controls language — potentially making compliance requirements more workable for your particular device design or intended use.
Jared Clark is the Principal Consultant at Certify Consulting, with 8+ years of FDA regulatory affairs experience serving 200+ clients with a 100% first-time audit pass rate. He holds credentials including JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, and RAC. For regulatory consulting services, visit certify.consulting.
Last updated: 2026-04-03
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.